Literature DB >> 10229403

Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets.

E Ekşioglu-Demiralp1, A Kibaroglu, H Direskeneli, S Yavuz, F Karsli, S Yurdakul, H Yazici, T Akoglu.   

Abstract

OBJECTIVE: Increased numbers of spontaneous Ig secreting B cells and elevated immunoglobulin levels have been described in Behçet's disease (BD), in addition to changes in numbers and activities of T cells, natural killer cells, and monocyte-macrophages. We investigated other characteristics of B cells in BD.
METHODS: B lymphocyte subsets (CD19+CD5+, CD19+CD13+, CD19+CD28+, CD19+CD33+, CD19+CD80+, CD5+CD19+CD45RA+, CD5+CD19+CD45RO+) were phenotypically evaluated in 50 patients with BD, 80 healthy subjects, and 20 other patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and sepsis.
RESULTS: Although the B cell number (CD19+) was normal, CD13 and CD33 positive B cells were more numerous in BD and sepsis compared to healthy controls and patients with RA and SLE. The percentage of CD45RO positive B cells was higher in both BD and sepsis, while the percentage of CD80 positive B cells was high only in BD. There was no increase in the CD5+CD19+ B cell subset, previously shown to be increased in several autoimmune diseases. Naive (CD45RA) and memory (CD45RO) status of CD5+CD19+ and CD5-CD19+ B cells showed that CD45RA expression was higher in CD5+CD19+ B cells, whereas expression of both CD45RA and CD45RO was higher in the CD5-CD19+ B cell group compared with healthy controls.
CONCLUSION: Although the total B cell number was normal, increased levels of activated and memory B cell subsets suggest a modified B cell function in BD, which may be related to a weak stimulus by an unknown external antigen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229403

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

Review 1.  Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51.

Authors:  H Direskeneli
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 2.  Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells.

Authors:  Salih Pay; Ismail Simşek; Hakan Erdem; Ayhan Dinç
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

Review 3.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

4.  The Presence of Autoantibodies Against Vascular and Nervous Tissue in Sera From Patients with Neuro-Behçet's Disease.

Authors:  Ayşe İlksen Colpak; Umut Kalyoncu; Yasemin Gürsoy Özdemir
Journal:  Noro Psikiyatr Ars       Date:  2014-06-01       Impact factor: 1.339

5.  Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis.

Authors:  Naomi Tsurikisawa; Hiroshi Saito; Chiyako Oshikata; Takahiro Tsuburai; Kazuo Akiyama
Journal:  J Clin Immunol       Date:  2013-04-27       Impact factor: 8.317

Review 6.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

7.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

8.  [Comments on the pathogenesis of Behçet's disease. A key to understanding new therapies?].

Authors:  U Pleyer; D Hazirolan; N Stübiger
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

9.  Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment.

Authors:  Fatmazohra Djaballah-Ider; Abdelhamid Djaballah; Zineb Djeraba; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2019-02-05       Impact factor: 4.473

Review 10.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Authors:  Andrew J Cowan; George S Laszlo; Elihu H Estey; Roland B Walter
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.